Axon Stock After Q3 2026: The Guide Cut Came From the Drones I Called Unproven

Axon cut its 2026 growth guide on November 5 and the stock fell about 18% on November 6. I think the cut is a drone-business problem, and the part of Axon that police agencies can't leave had a good quarter. The company says three federal deployments of Dedrone, its counter-drone system, worth about $130 million of revenue, won't ship this year. Without them, Axon says, growth would have been nearly 500 basis points higher, which is more than the whole cut.

That's the split I drew in September, when I wrote that Axon's lock is the court record. Evidence.com is the cloud where body-camera footage and other evidence sit and where prosecutors pull it for court. An agency that leaves has to re-prove the chain of custody on its open cases. Dedrone was the extra: one big quarter, padded by World Cup stadium security.

Axon doesn't report Dedrone on its own line. It sits in a hardware bucket called Platform Solutions, next to in-car video, interview-room cameras and drones. That bucket doubled from a year ago but fell from Q2, the quarter with the stadium shipments. On the call, President Josh Isner said the delays were mostly deal timing, but also Axon making sure it had the hardware to ship. So part of this is Axon's own supply, and that's on Axon.

I set two tests in September. The one about the record was recurring revenue growth under 20% for two quarters. It isn't close. Recurring revenue grew 40% and software and services sped up. Net revenue retention held at 126%, up from 124% a year earlier.

The Dedrone test was revenue under $100 million in both Q4 2026 and Q1 2027. Axon still doesn't disclose Dedrone revenue, and with $100 million of federal work pulled from the Q4 forecast, a weak Q4 is now likely. I've moved that test to watch. I also wrote that one Dedrone miss would just be a quarter where the product mix shifts. That undersold it. Counter-drone mix and memory chip costs together took hardware gross margin down about seven points. Axon also added over $100 million of inventory in Q3, especially for Dedrone, and cut its free cash flow guide.

Those are InvestMoat's live scores for Axon, each out of 100. After the print the framework cut the growth score, left the moat score alone, and the valuation score rose because the price fell. That's my read too. I'm not calling the drop a mistake. Lower growth and less cash are worth a lower price. I'm saying it doesn't tell you the lock got weaker.

The strongest bear point is that my clean split is less clean than the headline numbers suggest. Axon says its newer software (Dedrone software, real-time operations, records, AI and 911) is at a run rate near $500 million and more than doubling. My rough estimate is that this covers about half of the $132 million year-over-year rise in software and services. Strip it out and the older software, mostly Evidence.com and body-camera plans, grew somewhere in the high 20s. That's healthy, but it's slower than 43%, and some of the newer software rides on the same drones that just slipped.

The hardware outside Dedrone was weak too. TASER revenue dipped from a year ago, and connected devices excluding Platform Solutions were flat, at $346.6 million against $344.6 million. Isner said losing the Dedrone bookings makes the five-year bookings target a little more challenging. Memory is worse next year: the CFO put it at about 50 basis points of margin headwind in 2026 and more than four times that in 2027. And the long-term revenue target wasn't restated on this call.

Then Skydio. Axon put in another $1.2 billion, its largest single investment, to take a 37% stake in a drone maker it doesn't control and become its exclusive public-safety distributor in the U.S. and Canada. A bundle that extends itself doesn't usually need that check. Axon books that distribution revenue on a net basis in software and services, which is why my new test uses recurring revenue instead.

I take all of that as a growth case, and on growth the bear has the better of this quarter. It doesn't show an agency moving its evidence, and that's what would change my view of the moat.

The September piece was right about the lock and too relaxed about the cost of everything bolted onto it. I'd now say Axon is a court-record software business that grows by selling hardware into the same agencies, and that hardware brings procurement timing, memory costs and inventory into the guide. The moat holds. The growth rate the stock used to price in needed the extras to land on time, and in Q3 they didn't.

1. 1Late February 2027, the Q4 2026 report: recurring revenue growth. Below 30% and the slowdown has reached the record.
2. 2The same report: whether management confirms any of the three slipped federal Dedrone deployments shipped. Nothing by the Q1 2027 report, about May 2027, and I'll call them lost.
3. 3Dedrone itself: any revenue figure for Q4 2026 against the $100 million line from September.
4. 4Hardware gross margin through 2027, as memory costs rise to roughly four times this year's hit.
5. 5How much Skydio distribution revenue shows up inside software and services.